The Valeant Pipeline - Our Medicines in Development

Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. Its promising early and late-stage drug candidates have unique formulations and mechanisms of action that addresses the need for new treatment regimens for refractory disease and at-home emergency seizure management. Its pipeline candidates include retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and four new dermatology compounds topical anti-fungals and for the treatment of rosacea and oral acne. Valeant also plans to strategically expand its pipeline by adding new compounds and product extensions through company and product acquisitions.